Avantor, Inc.

Report azionario NYSE:AVTR

Capitalizzazione di mercato: US$5.5b

Avantor Gestione

Criteri Gestione verificati 2/4

Avantor Il CEO è Emmanuel Ligner, nominato in Aug2025, e ha un mandato di meno di un anno. la retribuzione annua totale è $ 5.90M, composta da 6.4% di stipendio e 93.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.013% delle azioni della società, per un valore di $ 710.74K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.7 anni e 2.7 anni.

Informazioni chiave

Emmanuel Ligner

Amministratore delegato

US$5.9m

Compenso totale

Percentuale dello stipendio del CEO6.43%
Mandato del CEOless than a year
Proprietà del CEO0.01%
Durata media del management2.7yrs
Durata media del Consiglio di amministrazione2.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Aggiornamento della narrazione May 01

AVTR: Reset Expectations And Execution Progress May Support Future Upside

Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.
Seeking Alpha Apr 30

Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible

Summary Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks. Valuation screens as discounted, but low multiples reflect market skepticism about AVTR’s growth durability and margin structure; a hold rating is maintained pending clearer evidence of turnaround. Read the full article on Seeking Alpha
Aggiornamento della narrazione Apr 16

AVTR: Expanded Quality Control Capabilities Will Support Execution Turnaround And Future Share Repricing

Analysts have trimmed their average price targets on Avantor, and the updated fair value estimate now stands at about $16.47. This reflects a softer sentiment around the stock as research notes point to share losses, reduced investment, and questions about management's ability to stabilize the business.
Aggiornamento della narrazione Apr 02

AVTR: Reset Expectations And Share Repurchases May Support Future Upside

The analyst price target for Avantor has shifted lower to reflect a series of Street target cuts, including a move to $8.50. This change stems from concerns about share losses, constrained investment, and uncertainty over whether management can stabilize the business.
Aggiornamento della narrazione Mar 19

AVTR: Execution Turnaround In Core Franchise Will Drive Future Share Repricing

Analysts have lowered their price targets on Avantor, with the updated fair value estimate moving from about $17.68 to $16.13 as they factor in concerns about share losses, underinvestment, and uncertainty around management's ability to stabilize the business, along with a higher assumed discount rate and P/E multiple. Analyst Commentary Recent Street research has tilted cautious on Avantor, highlighted by a downgrade to Underweight with a US$8.50 price target and several cuts to prior price targets.
Aggiornamento della narrazione Mar 05

AVTR: Reset Expectations And Buybacks Will Support Future Upside Potential

Analysts have cut their average price target on Avantor by a few dollars to reflect lower fair value estimates, softer assumed revenue growth and profit margins, and a higher future P/E multiple in light of recent broad target reductions from firms across the Street. Several have moved targets in a $2 to $4 range, and one reset its view from $14 to $12.
Articolo di analisi Feb 13

The Market Doesn't Like What It Sees From Avantor, Inc.'s (NYSE:AVTR) Revenues Yet As Shares Tumble 27%

Avantor, Inc. ( NYSE:AVTR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...
Aggiornamento della narrazione Feb 04

AVTR: Service Expansion And Execution Will Drive Upside From Reset Expectations

Narrative Update: Avantor Analyst Price Target Shift Analysts recently trimmed their price target on Avantor to $12 from $14. This reflects updated views on the life science tools sector and a Q4 outlook where many companies have already set softer expectations for 2026.
Aggiornamento della narrazione Jan 21

AVTR: Share Repurchases And Execution Risks Will Shape Turnaround Visibility

Analysts have trimmed their price target on Avantor by about $0.60, reflecting more cautious assumptions on revenue growth and future P/E. This is partly offset by slightly higher profit margin expectations and a marginally lower discount rate.
Aggiornamento della narrazione Jan 07

AVTR: Execution Turnaround And Review Process Will Unlock Share Repricing Potential

Avantor's analyst price targets and fair value estimates have inched higher to around $17.68 per share. At the same time, lower assumed revenue growth, a higher discount rate, a reduced future P/E, and sharply higher profit margin expectations reflect analysts' mixed views following recent downgrades and concerns about execution and visibility.
Aggiornamento della narrazione Dec 14

AVTR: Share Repurchases Will Drive Upside As Turnaround Visibility Improves

Analysts have modestly lowered their price targets on Avantor by a few dollars per share, generally to the low to mid teens in dollar terms. They cite reduced guidance, weaker quarters and limited visibility around the company’s turnaround and strategic review.
Aggiornamento della narrazione Nov 28

AVTR: Share Repurchase Initiative And Execution Will Shape Recovery Prospects Ahead

Analysts have lowered their price target for Avantor from $14 to $12 per share, citing a weak quarter, reduced guidance, and ongoing execution risks as primary concerns behind the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets ahead of quarterly results, reflecting improved confidence in Avantor’s long-term positioning despite current volatility.
Aggiornamento della narrazione Nov 14

AVTR: Share Repurchase And Execution Will Define Turnaround Prospects In 2025

Avantor’s analyst price target has decreased from $13.80 to $13.64. Analysts cite reduced company guidance, execution risks, and ongoing uncertainty surrounding its earnings outlook as key factors driving the revision.
Articolo di analisi Nov 01

Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

There's been a major selloff in Avantor, Inc. ( NYSE:AVTR ) shares in the week since it released its third-quarter...
Aggiornamento della narrazione Oct 31

AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery

Avantor’s analyst price target has been reduced from $14.40 to $13.80 per share, as analysts cite ongoing operational headwinds and limited near-term earnings visibility following recent downgrades and mixed guidance. Analyst Commentary Recent analyst notes on Avantor capture a divided outlook, reflecting both positive updates from some firms and notable caution from others as the company contends with ongoing operational challenges.
Articolo di analisi Oct 28

There's No Escaping Avantor, Inc.'s (NYSE:AVTR) Muted Earnings Despite A 28% Share Price Rise

Avantor, Inc. ( NYSE:AVTR ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...
Aggiornamento della narrazione Oct 16

Pharma Contracts And R&D Will Drive Growth Amid Price Pressures

Analysts have modestly increased their price target for Avantor, raising it by $0.28 to $14.40. They cite revised expectations for end market recovery and alignment with company outlooks.
Articolo di analisi Sep 12

We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Articolo di analisi Aug 12

Concerns Surrounding Avantor's (NYSE:AVTR) Performance

NYSE:AVTR 1 Year Share Price vs Fair Value Explore Avantor's Fair Values from the Community and select yours Avantor...
Articolo di analisi Jun 26

What Is Avantor, Inc.'s (NYSE:AVTR) Share Price Doing?

Avantor, Inc. ( NYSE:AVTR ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...
Seeking Alpha Apr 26

Avantor: A Healthier Diagnosis As Expectations Cool

Summary Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio. The risk-reward profile has improved due to lower expectations, but the outlook remains cautious amidst continued sales declines and pending leadership changes. Read the full article on Seeking Alpha
Seeking Alpha Mar 07

Avantor: Mundane Business, Solid Cash Flow, Potential New Risks

Summary Avantor, Inc. has seen a significant decline in its stock price recently. The company did divest itself of one business this summer, paying down some debt with the proceeds. In addition, the company delivered an impressive amount of free cash flow in FY2024. Buy, Sell or Hold?  An analysis around AVTR stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha Dec 18

Avantor: Durable FCF Generator Trading For Cheap

Summary Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor’s leadership in the biopharma industry and shifting revenue mix can produce considerable margin expansion. Significant FCF generation can improve the company’s capital structure and return value to shareholders. Potential industry inflection point creates optimal entry point with multiple expansion. Read the full article on Seeking Alpha
Seeking Alpha Oct 24

Avantor: Uninspiring, Even Amidst Some Green Shoots

Summary Avantor shares have struggled on the back of a high valuation, significant debt, and lackluster growth, despite recent improvements in organic sales and a divestment. The company operates two segments: a $4.7 billion laboratory solutions business, and a $2.2 billion bioscience production business, with the latter having higher margins. Recent financials show declining sales and earnings, amidst high valuation and a demanding valuation. A $650 million divestment aims to reduce debt, but the overall risk-reward remains unattractive given the company's past performance and high leverage. Read the full article on Seeking Alpha
User avatar
Nuova narrazione Aug 21

New Operating Model And Bioprocessing Innovations Promise Robust Growth And Market Leadership

Implementation of a new operating model and ongoing cost transformation initiatives are streamlining execution and improving net margins through cost savings.
Seeking Alpha Aug 13

Avantor: Yet To Evidence Economic Value For Valuation Repricing, Reiterate Hold

Summary AVTR stock is up 18% post Q2 FY'24 earnings, but momentum and quality continue to diverge. The company's balance sheet is saddled with debt, whilst earnings produced on capital are flattening. Valuations are unsupportive at >35x earnings, and I continue to rate AVTR a hold with little headroom for upside under present conditions. Read the full article on Seeking Alpha

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Emmanuel Ligner rispetto agli utili di Avantor?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$551m

Dec 31 2025US$6mUS$379k

-US$530m

Compensazione vs Mercato: La retribuzione totale di Emmanuel ($USD 5.90M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 8.38M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Emmanuel con le performance aziendali.


AMMINISTRATORE DELEGATO

Emmanuel Ligner (54 yo)

less than a year
Mandato
US$5,895,624
Compensazione

Mr. Emmanuel Ligner is President and Chief Executive Officer of Avantor, Inc. from August 18, 2025 and serves as its Director. He was Chief Executive Officer of Cerba HealthCare S.A.S. from March 01, 2024...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Emmanuel Ligner
Presidentless than a yearUS$5.90m0.013%
$ 710.7k
R. Jones
Executive VP & CFO2.8yrsUS$6.54m0.0059%
$ 324.3k
Claudius Sokenu
Executive VP2.8yrsUS$3.75m0.0033%
$ 184.6k
Corey Walker
President of Laboratory Solutions1.9yrsUS$5.99m0.0024%
$ 130.3k
Benoit Gourdier
Executive Vice President of Bioscience Production2.6yrsUS$5.23m0.0036%
$ 201.8k
Mary Blenn
Executive VP & COOless than a yearNessun datoNessun dato
Steven Eck
Senior VP7yrsNessun dato0.019%
$ 1.1m
Michael Wondrasch
Executive VP & Chief Information Officer8.1yrsUS$3.19mNessun dato
Chris Fidyk
Vice President of Investor Relationsless than a yearNessun datoNessun dato
Brittany Hankamer
Executive VP & Chief Human Resources Officer2.8yrsNessun dato0.036%
$ 2.0m
Christophe Couturier
Executive Vice President of AMEA8.1yrsNessun dato0.0088%
$ 486.2k
Ludovic Brellier
EVP of Bioscience & Medtech Products and Chief Transformation Officerno dataNessun datoNessun dato
2.7yrs
Durata media
55yo
Età media

Gestione esperta: Il team dirigenziale di AVTR è considerato esperto (durata media dell'incarico 2.7 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Emmanuel Ligner
Presidentno dataUS$5.90m0.013%
$ 710.7k
Gregory Summe
Independent Chairman of the Board6yrsUS$329.99k0.065%
$ 3.6m
Gregory Lucier
Independent Directorless than a yearUS$151.26k0.0088%
$ 487.3k
Pamela Makin
Independent Director1.5yrsUS$332.58k0.00070%
$ 38.8k
Joseph Massaro
Independent Director4.5yrsUS$329.99k0.0051%
$ 284.4k
Gerard Brophy
Chair of Scientific Advisory Board2.7yrsUS$3.09mNessun dato
Michael Severino
Independent Director6.1yrsUS$324.99k0.0064%
$ 352.6k
Johannes van der Loo
Member of Scientific Advisory Board2.7yrsNessun datoNessun dato
Mala Murthy
Independent Director4.6yrsUS$317.49k0.0040%
$ 220.1k
Brendan Hughes
Member of Scientific Advisory Board2.7yrsNessun datoNessun dato
Erik Sorensen
Member of Scientific Advisory Board2.7yrsNessun datoNessun dato
Stacy Springs
Member of Scientific Advisory Board2.3yrsNessun datoNessun dato
2.7yrs
Durata media
60yo
Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di AVTR non è considerato esperto (durata media del mandato 2.7 anni), il che suggerisce un nuovo consiglio.


Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/25 19:54
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Avantor, Inc. è coperta da 29 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Michael RyskinBofA Global Research